After showing the safety and effectiveness of the single-dose Johnson & Johnson Ad26.COV2.S Covid-19 vaccine in two studies, the Sisonke team published one of the first real-world studies on vaccine effectiveness against the Omicron variant in the New England Journal of Medicine on 4 May 2022.Trending, Headline, Johnson & JohnsonRead More